Former J&J exec charged with bribery
This article was originally published in The Gray Sheet
Executive Summary
Robert John Dougall, former VP of market development at J&J's DePuy International branch in Leeds, was charged with conspiracy to corrupt in a U.K. court Dec. 1. The former device exec is accused of "making corrupt payments and/or giving other inducements to medical professionals" in Greece between February 2002 and December 2005 to encourage them to purchase orthopedic products from J&J/DePuy, according to the U.K.'s Serious Fraud Office. The case was referred to the office by the U.S. Department of Justice in March 2008. Chief Magistrate District Judge Timothy Workman sent the case to England's Crown Court at Southwark, where Dougall is set to appear Feb. 3. Former worldwide chairman of J&J's medical device and diagnostics business Michael Dormer had stepped down in February 2007 after the company disclosed that foreign subsidiaries may have made improper payments in "two small-market countries" (1"The Gray Sheet" Feb. 19, 2007)
You may also be interested in...
Former J&J exec sentenced for bribery
Robert John Dougall, former marketing director at J&J's DePuy International branch in Leeds, is sentenced to 12 months in prison after pleading guilty to conspiracy to corrupt, the U.K.'s Serious Fraud Office announces April 14. Dougall admitted his involvement in a scheme to make payments or other inducements to medical professionals in Greece to encourage them to use J&J/DePuy's orthopedic devices. Between February 2002 and December 2005, the firm paid Greek doctors an estimated £4.5 million. The U.S. Department of Justice referred the case in October 2007 and SFO launched its investigation in March 2008 (1"The Gray Sheet" Dec. 7, 2009)
J&J Medical Device Chief Steps Down After Improper Payments Are Disclosed
Worldwide chairman of Johnson & Johnson's medical devices and diagnostics business Michael Dormer abruptly retired Feb. 12 following J&J's disclosure that foreign subsidiaries may have made improper payments in the course of marketing activities
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.